Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Histocompatibility and Donor Selection

Donor choice according to age for allo-SCT for AML in complete remission

Abstract

In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan–Meier-estimated 5-yr OS was better with UD 39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD 39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients 50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD 39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349–2361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 108: 3280–3288.

    Article  CAS  PubMed  Google Scholar 

  4. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043–2051.

    Article  CAS  PubMed  Google Scholar 

  5. Carreras E, Jiménez M, Gómez-García V, de la Cámara R, Martín C, Martínez F et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006; 37: 33–40.

    Article  CAS  PubMed  Google Scholar 

  6. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695–5702.

    Article  PubMed  Google Scholar 

  7. Helmberg W, Lanzer G, Zahn R, Weinmayr B, Wagner T, Albert E . Virtual DNA analysis—a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 1998; 51: 587–592.

    Article  CAS  PubMed  Google Scholar 

  8. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA et al. Nomenclature for factors of the HLA system. Tissue Antigens 2002; 60: 407–464.

    Article  CAS  PubMed  Google Scholar 

  9. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ et al. IMGT/HLA and IMGT/MHC: sequence database for the study of the major histocompatibility complex. Nucleic Acids Res 2003; 31: 311–314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2008; 41: 721–727.

    Article  CAS  PubMed  Google Scholar 

  11. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of Graft-versus-Host Disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 4: 295–30.

    Article  Google Scholar 

  12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Concensus conference on acute GvHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  13. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.

    Article  CAS  PubMed  Google Scholar 

  14. Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13–18.

    CAS  PubMed  Google Scholar 

  15. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.

    Article  CAS  PubMed  Google Scholar 

  16. Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et alATG-Fresenius Trial Group. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biol Blood Marrow Transplant 2012; 18: 1716–1726.

    Article  PubMed  Google Scholar 

  17. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H . Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003; 21: 506–513.

    Article  PubMed  Google Scholar 

  18. Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008; 36: 1047–1054.

    Article  CAS  PubMed  Google Scholar 

  19. Kröger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant 2009; 15: 454–462.

    Article  PubMed  Google Scholar 

  20. Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia 2013; 27: 604–609.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the nurses of the BMT wards for taking care of our patients, the study nurses for their assistance and the medical technicians and scientists for their work in the BMT laboratories.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F Ayuk.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ayuk, F., Zabelina, T., Wortmann, F. et al. Donor choice according to age for allo-SCT for AML in complete remission. Bone Marrow Transplant 48, 1028–1032 (2013). https://doi.org/10.1038/bmt.2013.14

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.14

Keywords

This article is cited by

Search

Quick links